{"key":"ss-31","slug":"ss-31","name":"SS-31","other_names":["SS31","Elamipretide","MTP-131","MTP131"],"kind":"single","area":{"slug":"longevity","name":"Skin and longevity"},"classification":"Mitochondria-targeted tetrapeptide (elamipretide)","standing":{"id":"phase-3","label":"Phase 3 trials","rank":4},"summary":"A four amino acid peptide that binds cardiolipin in the inner mitochondrial membrane. As elamipretide it has been through phase 3 trials and regulatory review for Barth syndrome.","cas_number":"736992-21-5","molecular_formula":"C32H49N9O5","molecular_weight":"639.8 g/mol","components":[],"has_article":false,"pubmed":{"papers":454,"in_humans":197,"clinical_trials":20},"retired":false,"updated_at":"2026-11-18T00:17:24.691Z","url":"https://pepts.wiki/compounds/ss-31","article":null,"evidence":{"query":"(elamipretide[tiab] OR \"SS-31\"[tiab] OR \"MTP-131\"[tiab])","fetched_at":"2026-11-16T23:07:24.281Z","counts":{"rcts":18,"human":197,"total":454,"reviews":94,"clinicalTrials":20},"years":[{"year":2012,"count":3},{"year":2013,"count":6},{"year":2014,"count":13},{"year":2015,"count":15},{"year":2016,"count":15},{"year":2017,"count":24},{"year":2018,"count":30},{"year":2019,"count":30},{"year":2020,"count":30},{"year":2021,"count":40},{"year":2022,"count":40},{"year":2023,"count":32},{"year":2024,"count":59},{"year":2025,"count":72},{"year":2026,"count":76}],"top":[{"doi":"10.1212/WNL.0000000000207402","url":"https://pubmed.ncbi.nlm.nih.gov/37268435/","kind":"rct","pmid":"37268435","year":2023,"title":"Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial","venue":"Neurology","authors":"Karaa A, Bertini E, Carelli V, et al."},{"doi":"10.1016/j.gim.2024.101138","url":"https://pubmed.ncbi.nlm.nih.gov/38602181/","kind":"rct","pmid":"38602181","year":2024,"title":"Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER","venue":"Genetics in medicine : official journal of the American College of Medical Genetics","authors":"Thompson WR, Manuel R, Abbruscato A, et al."},{"doi":"10.1016/j.jacc.2024.08.014","url":"https://pubmed.ncbi.nlm.nih.gov/39217569/","kind":"rct","pmid":"39217569","year":2024,"title":"Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM","venue":"Journal of the American College of Cardiology","authors":"Sherrod CF 4th, Saberi S, Nassif ME, et al."},{"doi":"10.1186/s13023-024-03421-5","url":"https://pubmed.ncbi.nlm.nih.gov/39574155/","kind":"rct","pmid":"39574155","year":2024,"title":"Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial","venue":"Orphanet journal of rare diseases","authors":"Karaa A, Bertini E, Carelli V, et al."},{"doi":"10.1186/s13023-023-02676-8","url":"https://pubmed.ncbi.nlm.nih.gov/37041653/","kind":"rct","pmid":"37041653","year":2023,"title":"Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data","venue":"Orphanet journal of rare diseases","authors":"Van den Eynde J, Chinni B, Vernon H, et al."},{"doi":"10.1177/2048872617710789","url":"https://pubmed.ncbi.nlm.nih.gov/28534645/","kind":"rct","pmid":"28534645","year":2019,"title":"The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction","venue":"European heart journal. Acute cardiovascular care","authors":"Hortmann M, Robinson S, Mohr M, et al."},{"doi":"10.1093/ajhp/zxaf303","url":"https://pubmed.ncbi.nlm.nih.gov/41206662/","kind":"study","pmid":"41206662","year":2026,"title":"Elamipretide Hydrochloride","venue":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","authors":""},{"doi":"10.1186/s12974-019-1627-9","url":"https://pubmed.ncbi.nlm.nih.gov/31747905/","kind":"study","pmid":"31747905","year":2019,"title":"Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice","venue":"Journal of neuroinflammation","authors":"Zhao W, Xu Z, Cao J, et al."},{"doi":"10.3390/ijms26030944","url":"https://pubmed.ncbi.nlm.nih.gov/39940712/","kind":"review","pmid":"39940712","year":2025,"title":"Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential","venue":"International journal of molecular sciences","authors":"Tung C, Varzideh F, Farroni E, et al."},{"doi":"10.1007/s40265-025-02269-8","url":"https://pubmed.ncbi.nlm.nih.gov/41335372/","kind":"review","pmid":"41335372","year":2026,"title":"Elamipretide: First Approval","venue":"Drugs","authors":"Shirley M"}]},"library_version":"183:2026-11-17T11:05:42.386Z","attribution":"Data from Pepts.wiki (https://pepts.wiki), CC BY 4.0. Link back to the compound's page.","notice":"We are not doctors, and nothing on Pepts.wiki is medical advice or a recommendation to use anything. The wiki sets out what studies measured, as clearly and evenly as it can, so you can make better-informed decisions. Always consult a medical professional before acting on anything you read here."}